机器学习在分布式数据网络中用于药物流行病学与药物警戒研究的机遇、挑战与考量
本文讨论在分布式数据网络(DDN)中应用机器学习(ML)开展药物流行病学与药物警戒研究的机遇、挑战与考量。文章先梳理DDN的主要活动类型及ML可能用途,再分析影响DDN实践的数据相关因素,并联合考量这些因素如何影响ML机遇及应对策略,指出尽管存在挑战,ML在DDN中的应用时机已成熟。
要点
- DDN架构可协调多数据库研究,提升药物流行病学与药物警戒研究效率。
- ML能自动建模高维数据复杂关联,但DDN的数据孤岛与异质性带来独特挑战。
- 文章提出应对挑战的方法及现实DDN的缓解措施,ML应用效用预计将持续增加。
核心结论
- 尽管在DDN中应用ML面临挑战,但开展ML用于药物流行病学与药物警戒研究的时机已成熟,其效用未来可能继续增加。
研究设计与样本
- 本文为方法学讨论文章,围绕在DDN中应用ML开展药物流行病学与药物警戒研究的机遇、挑战与考量进行论述。
主要发现
- DDN中电子健康数据量增大,促使人们关注可自动建模高维数据复杂关联的数据自适应ML技术。
- DDN中数据库的孤岛式存储与多样性给ML使用带来独特挑战。
- 文章识别了影响DDN实践的数据相关因素,并联合考量这些因素如何影响ML机遇,进而引出若干挑战。
关键数值与推荐
- 文章讨论了DDN开展的主要活动类型及ML可能的用途。
- 文章提出了应对ML在DDN中应用挑战的不同方法,并强调现实DDN已采取或正在采取的缓解措施。
临床怎么用
- 临床药学智能体医生在参与多数据库药物流行病学或药物警戒研究时,可参考本文框架评估ML在DDN中的适用性与数据相关限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Increasing availability of electronic health databases capturing real-world experiences with medical products has garnered much interest in their use for pharmacoepidemiologic and pharmacovigilance studies. The traditional practice of having numerous groups use single databases to accomplish similar tasks and address common questions about medical products can be made more efficient through well-coordinated multi-database studies, greatly facilitated through distributed data network (DDN) architectures. Access to larger amounts of electronic health data within DDNs has created a growing interest in using data-adaptive machine learning (ML) techniques that can automatically model complex associations in high-dimensional data with minimal human guidance. However, the siloed storage and diverse nature of the databases in DDNs create unique challenges for using ML. In this paper, we discuss opportunities, challenges, and considerations for applying ML in DDNs for pharmacoepidemiologic and pharmacovigilance studies. We first discuss major types of activities performed by DDNs and how ML may be used. Next, we discuss practical data-related factors influencing how DDNs work in practice. We then combine these discussions and jointly consider how opportunities for ML are affected by practical data-related factors for DDNs, leading to several challenges. We present different approaches for addressing these challenges and highlight efforts that real-world DDNs have taken or are currently taking to help mitigate them. Despite these challenges, the time is ripe for the emerging interest to use ML in DDNs, and the utility of these data-adaptive modeling techniques in pharmacoepidemiologic and pharmacovigilance studies will likely continue to increase in the coming years.
引用
- Wong J, Prieto-Alhambra D, Rijnbeek PR, et al. Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations. Drug Saf. 2022. PMID: 35579813. doi:10.1007/s40264-022-01158-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。